Elevation Oncology Inc [NASDAQ: ELEV] gained 10.79% or 0.07 points to close at $0.72 with a heavy trading volume of 40502123 shares.
The daily chart for ELEV points out that the company has recorded -74.98% loss over the past six months.
If we look at the average trading volume of 1.04M shares, ELEV reached to a volume of 40502123 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Elevation Oncology Inc [ELEV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ELEV shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ELEV stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Elevation Oncology Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 03, 2025. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on May 31, 2024, representing the official price target for Elevation Oncology Inc stock. Previously, the target price had yet another raise to $8, while Stephens analysts kept a Overweight rating on ELEV stock.
The Average True Range (ATR) for Elevation Oncology Inc is set at 0.10 The Price to Book ratio for the last quarter was 0.61, with the Price to Cash per share for the same quarter was set at 1.74.
Trading performance analysis for ELEV stock
Elevation Oncology Inc [ELEV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.56. With this latest performance, ELEV shares dropped by -3.29% in over the last four-week period, additionally sinking by -74.98% over the last 6 months – not to mention a drop of -67.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ELEV stock in for the last two-week period is set at 55.66, with the RSI for the last a single of trading hit 55.84, and the three-weeks RSI is set at 54.62 for Elevation Oncology Inc [ELEV]. The present Moving Average for the last 50 days of trading for this stock 0.6221, while it was recorded at 0.7586 for the last single week of trading, and 1.9254 for the last 200 days.
Elevation Oncology Inc [ELEV]: A deeper dive into fundamental analysis
Elevation Oncology Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 17.77 and a Current Ratio set at 17.77.
An analysis of Institutional ownership at Elevation Oncology Inc [ELEV]
There are presently around $83.86%, or 84.08%% of ELEV stock, in the hands of institutional investors. The top three institutional holders of ELEV stocks are: LOGOS GLOBAL MANAGEMENT LP with ownership of 3.85 million shares, which is approximately 6.5234%. FARALLON CAPITAL MANAGEMENT LLC, holding 3.6 million shares of the stock with an approximate value of $$9.72 million in ELEV stocks shares; and FARALLON CAPITAL MANAGEMENT LLC, currently with $$8.26 million in ELEV stock with ownership which is approximately 5.1848%.
